Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting

2002, Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report, Circulation, 106, 3143, 10.1161/circ.106.25.3143 Ward, 2007, A systematic review and economic evaluation of statins for the prevention of coronary events, Health Technol Assess, 11, 1, 10.3310/hta11140 Kashani, 2006, Risks associated with statin therapy: a systematic overview of randomized clinical trials, Circulation, 114, 2788, 10.1161/CIRCULATIONAHA.106.624890 Harper, 2007, The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis, Curr Opin Lipidol, 18, 401, 10.1097/MOL.0b013e32825a6773 Thompson, 2003, Statin-associated myopathy, JAMA, 289, 1681, 10.1001/jama.289.13.1681 Hedenmalm, 2010, Muscle toxicity with statins, Pharmacoepidemiol Drug Saf, 19, 223, 10.1002/pds.1895 Andrade, 2005, Health plan administrative databases can efficiently identify serious myopathy and rhabdomyolysis, J Clin Epidemiol, 58, 171, 10.1016/j.jclinepi.2004.10.004 Graham, 2004, Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs, JAMA, 292, 2585, 10.1001/jama.292.21.2585 Furberg, 2001, Withdrawal of cerivastatin from the world market, Curr Control Trials Cardiovasc Med, 2, 205, 10.1186/CVM-2-5-205 Fontanarosa, 2004, Postmarketing surveillance—lack of vigilance, lack of trust, JAMA, 292, 2647, 10.1001/jama.292.21.2647 Bullano, 2006, Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting, Pharmacotherapy, 26, 469, 10.1592/phco.26.4.469 Bullano, 2007, Effectiveness of rosuvastatin versus atorvastatin in reducing lipid levels and achieving low-density-lipoprotein cholesterol goals in a usual care setting, Am J Health Syst Pharm, 64, 276, 10.2146/060104 Cziraky, 2006, Statin safety: an assessment using an administrative claims database, Am J Cardiol, 97, 61C, 10.1016/j.amjcard.2005.12.011 Ernster, 1994, Nested case-control studies, Prev Med, 23, 587, 10.1006/pmed.1994.1093 Pang, 1999, A relative power table for nested matched case-control studies, Occup Environ Med, 56, 67, 10.1136/oem.56.1.67 Staffa, 2002, Cerivastatin and reports of fatal rhabdomyolysis, N Engl J Med, 346, 539, 10.1056/NEJM200202143460721 Cottrell, 2003, Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome, Curr Opin Cardiol, 18, 301, 10.1097/00001573-200307000-00010 Tenenbaum, 2006, Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins, Cardiovasc Diabetol, 5, 20, 10.1186/1475-2840-5-20 Mosca, 2005, Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting, Circulation, 111, 488, 10.1161/01.CIR.0000153859.66086.85 Zielinski, 2005, FDA attempting to overcome major roadblocks in monitoring drug safety, J Natl Cancer Inst, 97, 872, 10.1093/jnci/97.12.872 McAdams, 2008, Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis, Pharmacoepidemiol Drug Saf, 17, 229, 10.1002/pds.1535 Nichols, 2007, Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients, Clin Ther, 29, 1761, 10.1016/j.clinthera.2007.08.022 Fung, 2010, Patients' perspectives on nonadherence to statin therapy: a focus-group study, Permanente J, 14, 4, 10.7812/TPP/09-090 Schech, 2007, Risk factors for statin-associated rhabdomyolysis, Pharmacoepidemiol Drug Saf, 16, 352, 10.1002/pds.1287